The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Hemosure sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Hemosure is a medical device company that manufactures immunological fecal immunochemical testing products. It offers sure click cup drug of abuse, fecal occult blood testing, first sign, accu-reader, ovutell, first sign drug of abuse, and other products. The company’s major product, fecal occult blood testing is a revolutionizing fit test that can detect and give positive results for high levels of hemoglobin. Hemosure is headquartered in Irwindale, California, the US.
The key metrics of Hemosure related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Hemosure is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Hemosure.
For a detailed understanding of the performance of Hemosure, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.